Lynn Anne Bristol

Array ( [id] => 17990199 [patent_doc_number] => 20220356236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/809941 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982610 [patent_doc_number] => 20220348646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/809943 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497469 [patent_doc_number] => 20230220110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/851989 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329713 [patent_doc_number] => 12459979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Modified chimeric antigen receptors and methods of use [patent_app_type] => utility [patent_app_number] => 17/847597 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 12 [patent_no_of_words] => 19846 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329713 [patent_doc_number] => 12459979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Modified chimeric antigen receptors and methods of use [patent_app_type] => utility [patent_app_number] => 17/847597 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 12 [patent_no_of_words] => 19846 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484995 [patent_doc_number] => 20230212312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/837633 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18161401 [patent_doc_number] => 20230027993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => METHODS [patent_app_type] => utility [patent_app_number] => 17/832307 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036251 [patent_doc_number] => 20220380466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS FOR TREATMENT OF B CELL PROLIFERATIVE DISORDERS WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/829807 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18376010 [patent_doc_number] => 20230151092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => CD229 Car T Cells And Methods Of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/827242 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17827242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982597 [patent_doc_number] => 20220348633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/735197 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036244 [patent_doc_number] => 20220380459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/736031 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929865 [patent_doc_number] => 20220324990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/720954 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17720954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929865 [patent_doc_number] => 20220324990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/720954 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17720954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734732 [patent_doc_number] => 20220220191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/709592 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960102 [patent_doc_number] => 20220340682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => ANTI-CEACAM5 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/705016 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855583 [patent_doc_number] => 12258406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Antibodies that bind CD3 Epsilon [patent_app_type] => utility [patent_app_number] => 17/702660 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 66 [patent_no_of_words] => 25565 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179986 [patent_doc_number] => 20230040715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/701764 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913259 [patent_doc_number] => 20220315654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/701570 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 685 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913259 [patent_doc_number] => 20220315654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/701570 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 685 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687772 [patent_doc_number] => 20220195064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-CD371 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/692979 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692979 [rel_patent_id] =>[rel_patent_doc_number] =>)